Shilpa Medicare's Ondansetron injection gets SEC final approval

Shilpa Medicare's Ondansetron injection gets SEC final approval. The company’s novel OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) has received final approval from the Subject Expert Committee for marketing authorization. This clears a key regulatory hurdle for commercialization in India. Approval boosts prospects for revenue from complex generics in the injectables segment.

📊 STOCKS: $SHILPAM | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma